background
emerg
diseas
caus
viru
specif
medic
identifi
date
aim
investig
administ
medic
intervent
time
patient
complet
recov
method
singlecent
retrospect
observ
studi
includ
patient
transfer
shenyang
sixth
peopl
hospit
januari
march
demograph
inform
symptom
laboratori
indic
treatment
process
clinic
outcom
collect
administ
drug
intervent
time
compar
eight
patient
mild
sever
symptom
respect
find
patient
recov
fiftythre
patient
receiv
antivir
therapi
includ
mild
group
median
treatment
day
receiv
umifenovir
eight
severegroup
patient
median
treatment
day
four
receiv
lopinavirritonavir
twentynin
patient
administ
antibiot
includ
mild
group
median
treatment
day
receiv
moxifloxacin
eight
sever
group
median
treatment
day
two
receiv
linezolid
moreov
seven
patient
treat
glucocorticoid
nine
immunomodul
pathogenesi
infect
remain
unclear
effect
drug
regimen
treatment
identifi
china
nation
recommend
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
trialbas
antivir
symptommanag
drug
administ
retrospect
review
type
dose
clinic
drug
cours
treatment
intervent
time
patient
cure
would
highli
inform
treat
patient
diseas
worldwid
data
medic
administ
patient
ultim
recov
scarc
crucial
clinician
end
investig
patient
confirm
complet
recov
transfer
shenyang
sixth
peopl
hospit
design
treatment
facil
liaon
provinc
studi
includ
data
patient
mild
sever
symptom
help
identifi
drug
administr
method
requir
differ
stage
diseas
help
patient
recov
perform
singlecent
retrospect
observ
studi
shenyang
sixth
peopl
hospit
shenyang
liaon
china
governmentdesign
central
medic
facil
treatment
patient
liaon
provinc
patient
hospit
receiv
patient
initi
treatment
seven
citi
liaon
provinc
includ
shenyang
chest
hospit
accord
interim
guidelin
issu
world
health
organ
januari
patient
throat
swab
sputum
sampl
collect
subject
nucleic
acid
rna
test
includ
consecut
patient
treat
januari
march
none
exclud
patient
consid
mild
group
mildmoder
wherea
consid
sever
group
severecrit
classif
accord
criteria
state
diagnosi
treatment
plan
issu
nation
health
commiss
peopl
republ
china
studi
review
approv
ethic
committe
shenyang
chest
hospit
approv
number
also
document
ethic
committe
shenyang
sixth
peopl
hospit
written
inform
consent
form
waiv
owe
rapid
develop
infecti
diseas
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
review
clinic
manifest
well
laboratori
radiolog
find
enrol
patient
collect
data
includ
age
sex
epidemiolog
histori
past
histori
symptom
complic
laboratori
indic
therapeut
drug
intervent
time
endpoint
total
patient
recoveri
rate
individu
meet
discharg
criteria
includ
recov
statist
discharg
criteria
consist
china
diagnosi
treatment
plan
follow
bodi
temperatur
return
normal
remain
least
day
respiratori
symptom
appreci
reliev
pulmonari
imag
show
signific
improv
acut
exud
lesion
nucleic
acid
test
sputum
nasopharyng
swab
respiratori
specimen
neg
twice
consecut
follow
minimum
interv
hour
given
purpos
studi
examin
clinic
characterist
drug
administr
data
patient
formal
hypothesi
establish
calcul
optim
sampl
size
continu
variabl
express
mean
standard
deviat
median
interquartil
rang
iqr
categor
variabl
denot
percentag
mean
age
patient
studi
year
among
male
wuhanhubei
complic
chronic
diseas
lung
comput
tomographi
scan
show
local
diffus
infiltr
shadow
patient
wherea
remain
patient
inflammatori
chang
patient
mild
group
eight
sever
group
tabl
common
symptom
fever
cough
seventeen
patient
complic
liver
function
impair
hypoxemia
two
acut
respiratori
distress
syndrom
ard
tabl
white
blood
cell
count
lymphocyt
count
percentag
lymphocyt
count
patient
mild
group
normal
rang
although
creactiv
protein
level
mgl
elev
sever
group
howev
lymphocyt
count
l
percentag
lymphocyt
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
suppress
creactiv
protein
level
mgl
elev
tabl
mild
sever
group
median
durat
lymphocyt
count
return
normal
day
respect
lung
shadow
markedli
improv
day
respect
achiev
neg
rna
convers
day
respect
figur
fiftythre
patient
receiv
antivir
therapi
median
time
day
iqr
day
two
patient
administ
antivir
drug
one
pregnant
woman
asymptomat
infect
among
receiv
antivir
drug
mild
group
group
median
treatment
time
day
iqr
day
treat
umifenovir
umifenovir
lopinavirritonavir
five
lopinavirritonavir
moreov
eight
patient
sever
group
receiv
antivir
drug
median
treatment
time
day
iqr
day
four
patient
sever
group
treat
lopinavirritonavir
three
umifenovir
lopinavirritonavir
one
umifenovir
twentynin
patient
treat
antibiot
median
time
day
iqr
patient
treat
moxifloxacin
three
receiv
linezolid
among
patient
treat
antibiot
mild
group
group
median
treatment
time
day
iqr
day
treat
moxifloxacin
two
receiv
carrimycin
remain
antibiot
recipi
compris
eight
patient
sever
group
median
treatment
time
day
iqr
four
patient
treat
moxifloxacin
two
linezolid
seven
patient
treat
glucocorticoid
receiv
recombin
human
interferon
nine
treat
thymalfasin
figur
patient
present
studi
achiev
recoveri
rate
effect
antivir
drug
treat
identifi
date
opinion
whether
antivir
drug
even
use
treat
differ
nation
health
commiss
peopl
republ
china
repeatedli
issu
revis
diagnosi
treatment
plan
recommend
antivir
drug
lopinavirritonavir
ribavirin
umifenovir
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
alphainterferon
present
studi
patient
receiv
antivir
therapi
earli
cours
diseas
median
time
day
iqr
day
mild
group
patient
treat
umifenovir
anoth
receiv
combin
umifenovir
lopinavirritonavir
median
time
day
iqr
day
liu
et
al
ribavirin
interferon
also
mention
diagnosi
treatment
plan
present
studi
four
patient
mild
group
administ
ribavirin
combin
antivir
therapi
nucleosid
analog
theoret
ought
possess
anticoronaviru
activ
certain
extent
howev
ribavirin
found
minim
antivir
effect
coronaviru
vitro
present
studi
patient
receiv
aerosol
inhal
alphainterferon
soon
diagnosi
twice
per
day
retrospect
studi
patient
middl
east
respiratori
syndrom
mer
show
interferon
acceler
viru
clearanc
studi
patient
sar
show
alphainterferon
improv
patient
prognosi
present
studi
small
number
patient
treat
ribavirin
alphainterferon
simpli
use
assist
aerosol
inhal
therefor
use
two
drug
patient
difficult
evalu
term
antimicrobi
use
recommend
empir
antimicrobi
therapi
base
clinic
diagnosi
china
diagnosi
treatment
plan
also
emphas
avoid
blind
inappropri
use
antibiot
kim
et
al
found
patient
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
recommend
systemat
use
glucocorticoid
viral
pneumonia
concurr
ard
china
diagnosi
treatment
plan
recommend
hormon
adjuv
therapi
present
studi
patient
receiv
glucocorticoid
receiv
agent
rapid
progress
diseas
inhibit
inflamm
improv
oxygen
dose
mgkgday
treatment
gradual
reduc
day
discontinu
show
advers
reaction
glucocorticoid
appear
unnecessari
patient
mild
manifest
use
treat
patient
sever
diseas
controversi
china
diagnosi
treatment
plan
suggest
immunotherapi
attempt
patient
sever
present
studi
patient
administ
thymalfasin
addit
evid
gather
regard
effect
immunomodulatori
drug
viral
pneumonia
henc
notion
requir
clinic
observ
studi
highflow
oxygen
therapi
invas
mechan
ventil
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
extracorpor
membran
oxygen
provid
patient
present
studi
use
investig
find
suggest
specif
antivir
drug
yet
develop
current
avail
antivir
agent
consid
treat
patient
prophylact
administr
singl
antivir
drug
patient
sever
symptom
well
proport
mild
manifest
may
help
reduc
risk
coinfect
howev
use
glucocorticoid
immunomodul
need
studi
studi
limit
given
singlecent
retrospect
observ
natur
owe
small
sampl
size
descript
data
avail
statist
analys
perform
henc
random
doubleblind
control
trial
remain
necessari
accur
conclus
nevertheless
data
ought
provid
help
preliminari
inform
stage
pandem
yu
chen
yongyu
liu
design
studi
chang
liu
na
li
respons
literatur
search
author
declar
compet
interest
studi
fund
shenyang
major
scienc
technolog
innov
r
program
chen
thank
patient
involv
studi
would
like
thank
editag
wwweditagecn
english
languag
edit
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
alanin
aminotransferas
ul
creatinin
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
